London, Ontario (January 9, 2012): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that the Company will meet with several prospective licensing partners including executives from major pharmaceutical organizations who have expressed interest in its lead oncology drug candidate COTI‐2 at Biotech Showcase. Biotech Showcase is a pharmaceutical partnering conference held concurrent to J.P. Morgan's 30th annual Healthcare Conference taking place in San Francisco, California on January 9‐11, 2012.

The objective of these meetings is to present compelling data on COTI‐2, a potentially first‐in‐class and best‐in‐class non‐ATP competitive modulator of AKT2, and to further discussions surrounding a licensing deal. “We are delighted with the continued development of our lead oncology candidate, COTI‐2,” said Dr. Wayne Danter, Chief Executive Officer of COTI. “The most recent results suggest COTI‐2 is a highly selective, orally effective and well tolerated drug candidate that is well positioned for clinical development. We are seeking a partner with an interest in moving this novel, targeted anti‐cancer drug candidate through development and to the market in indications where significant unmet medical need exists.”

During preclinical testing, COTI‐2 has demonstrated greater selectivity, an improved safety profile and superior pharmacokinetics in comparison to other AKT targeted compounds. Over expression of AKT/AKT2 is common in a broad range of human cancers, including ovarian, endometrial, pancreatic, breast, colorectal and lung. The percent of tumors with active AKT/AKT2 range from 20% to 100% depending on the cancer type.